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A B S T R A C T
Human peroxidasin 1 (PXDN) is a homotrimeric multidomain heme peroxidase and essential for tissue devel-
opment and architecture. It has a biosynthetic function and catalyses the hypobromous acid-mediated formation
of specific covalent sulfilimine (S]N) bonds, which cross-link type IV collagen chains in basement membranes.
Currently, it is unknown whether and which domain(s) [i.e. leucine-rich repeat domain (LRR), immunoglobulin
domains, peroxidase domain, von Willebrand factor type C domain] of PXDN interact with the polymeric net-
works of the extracellular matrix (ECM), and how these interactions integrate and regulate the enzyme's cross-
linking activity, without imparting oxidative damage to the ECM. In this study, we probed the interactions of
four PXDN constructs with different domain compositions with components of a basement membrane extract by
immunoprecipitation. Strong binding of the LRR-containing construct was detected with the major ECM protein
laminin. Analysis of these interactions by surface plasmon resonance spectroscopy revealed similar kinetics and
affinities of binding of the LRR-containing construct to human and murine laminin-111, with calculated dis-
sociation constants of 1.0 and 1.5 μM, respectively. The findings are discussed with respect to the recently
published in-solution structures of the PXDN constructs and the proposed biological role of this peroxidase.
1. Introduction
Basement membranes (BMs) are widely-distributed cell-adherent
specialized extracellular matrices (ECMs), that provide a complex fra-
mework that segregates polarized epithelial or endothelial cells from
the underlying mesenchyme [1,2]. The emergence of BMs coincided
with the origin of multicellularity in animals, suggesting that they are
essential for the formation of tissues. BMs provide structural support to
tissues and play active roles in many developmental processes including
organogenesis, angiogenesis and tissue repair [3]. Their sheet-like
structure derives from two independent polymeric networks derived
from two major protein classes: the laminins and type IV collagen [4].
These (independent) networks interact with each other via additional
ECM proteins including agrin, nidogen, entactin and perlecan [3].
Laminins are cross-shaped heterotrimers (αβγ) that share a common
structure with a number of globular and rod-like domains [5,6]. In
vertebrates, five α, three β, and three γ chains are assembled in
different combinations generating a large variety of isoforms which are
believed to have distinct functions in embryogenesis, vascular ma-
turation, and neuromuscular development [7]. For example, the iso-
form laminin-111 (i.e. α1β1γ1) plays an important role in the early
embryonic development in mammals [7].
Previous studies have shown that the ECM proteins are highly sus-
ceptible to oxidative damage due to their high abundance, their low
rate of turnover, and the relatively low levels of extracellular anti-
oxidants, repair and catabolic systems [8]. Oxidants can induce struc-
tural and functional changes to laminins and other ECM materials, with
damage evident in multiple tissue samples, including human athero-
sclerotic lesions [9–11]. It has been hypothesized that co-localisation of
hypohalous acid-producing myeloperoxidase (MPO) with ECM com-
ponents might be involved in the observed oxidative damage, since
MPO undergoes transcytosis across endothelial cells and binds tightly to
sub-endothelial and glomerular BM [12] and particularly fibronectin
[13]. MPO also directly binds to perlecan via an electrostatic
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interaction established between cationic MPO and the anionic side
chains of perlecan [14].
Recently, a related human peroxidase, peroxidasin 1 (PXDN) was
detected within the ECM network [15,16]. In contrast to MPO (which
exhibits antimicrobial activity and is part of the innate immune
system), PXDN has been shown to have a biosynthetic function and to
mediate the formation of specific covalent sulfilimine (S]N) bonds that
cross-link type IV collagen chains in BMs. In contrast to MPO (and other
homologous human peroxidases), PXDN is a multi-domain, highly-
glycosylated, homotrimeric peroxidase [17,18] and a member of Family
2 of the peroxidase-cyclooxygenase superfamily [19,20]. It catalyses
the hydrogen peroxide-mediated oxidation of bromide to hypobromous
acid [21], which mediates S]N bond formation between specific (hy-
droxy)lysine and methionine residues at the interface of two NC1-do-
main trimers of type IV collagen [15,16,22]. Removal of the substrate
bromide, and hence prevention of cross-linking, is embryonically lethal
in Drosophila melanogaster and Caenorhabditis elegans [16]. Thus, per-
oxidasin 1 catalyses a post-translational modification that is essential
for tissue development and architecture.
To date, it is unknown how peroxidasin 1 is embedded in the ECM,
and how it is able to catalyse the formation of specific sulfilimine bonds
in type IV collagen without inducing (collateral) oxidative damage to
other sites on the collagen chains, or other BM molecules. In particular,
the role(s) of specific PXDN-typical domains, including the N-terminal
leucine-rich repeat domain (LRR), the immunoglobulin domains (Ig),
and the C-terminal von Willebrand factor type C module (VWC)
[17,18], which are all known to be important for protein-protein in-
teractions and cell adhesion [22], are unknown. Therefore, we have
designed and produced four recombinant and truncated PXDN variants
with different domain compositions in order to identify potential BM
binding partners by co-immunoprecipitation (IP). We have un-
ambiguously identified laminin as a binding partner of PXDN and de-
monstrate that the LRR domain promotes high affinity binding to
murine and human laminin-111 with very similar KD values, as de-
termined by surface plasmon resonance (SPR) spectroscopy.
2. Material and methods
2.1. Materials
High purity murine laminin (muLN111) free of entactin (Corning®
Ultrapure Laminin) was purchased from Corning Incorporated, USA.
Human laminin isoforms (huLN111, huLN411) were from Biolamina
AB, Sweden. Laminin concentrations were determined via the UV–vis
absorption at 280 nm and based on molar masses of 900 and 713 kDa
(muLN111 and huLN111) or 579 kDa (huLN411). Murine basement
membrane extract (BME) with reduced growth factors (Cultrex) was
purchased from Trevigen. Protein G Dynabeads were obtained from
Thermofisher. The anti-His6 antibody monoclonal antibody and rabbit
anti-laminin polyclonal antibody, were purchased from Abcam, and the
secondary anti-rabbit IgG conjugated with horseradish peroxidase an-
tibody was purchased from GE. Other chemicals were purchased from
Sigma at the highest grade available.
2.2. Cloning, expression and purification of constructs
We have cloned and recombinantly produced four PXDN constructs,
namely PXDN-con2, PXDN-con3, PXDN-con4, and PXDN-con5 (Fig. 1).
UniProt KB (http://www.uniprot.org/) data on human peroxidasin 1
(Q92626) provided the basis for primer design. DNA of PXDN-con 2 (Pro246-
Leu1471), PXDN-con 3 (Val27-Asp1314), PXDN-con 4 (Pro246-Asp1314) and
PXDN-con 5 (Gly619-Asp1314) were cloned into a modified gWiz vector
(Genlantis) carrying an N-terminal His6 tag for protein purification. Forward
and reverse PCR primers were as follows: PXDN-con2: 5′- gaggctcaccac-
caccatcac catccccgaatcacctccgagccc -3′ and 5′-agccagaagtgatctggatctca-
taagcagactggacagcaggc-3’; PXDN-con3: 5′-gaggctcaccaccaccatcaccatgtgg-
tggcccagaagccggg-3'and 5′-tagccagaagtgatctggatctcagtcctgccacacccggaggtc-
3’; PXDN-con4: 5′-gctctgggttccaggttccactggccatcatcaccatcaccatggagatcc-
gtttgtagctacctccatcg-3′ and 5′-gccagaggtcgaggtcgggggatccttatcagtcctgcca-
cacccggaggtccaccctgggg-3′; PXDN-con4: same forward primer as for PXDN-
con5 and 5′-gccagaggtcgaggtcgggggatccttatcaactgag- ccgtgattcaagtttctttatc-
3′. Transformed E. coli XL-10 were screened via colony-PCR and positive
clones were selected and validated by DNA sequencing.
Abbreviations
PXDN human peroxidasin 1
LRR leucine-rich repeat domain
Ig immunoglobulin domain
VWC C-terminal von Willebrand factor type C
POX peroxidase domain
ECM extracellular matrix
BM basement membrane
BME basement membrane extract
LN laminin
huLN human laminin
muLN murine laminin
MPO myeloperoxidase
LPO lactoperoxidase
EPO eosinophil peroxidase
TPO thyroid peroxidase
PBS phosphate buffer-saline
PBST phosphate buffer-saline + Tween 20
IP immunoprecipitation
SAXS small-angle X-ray scattering
SPR surface plasmon resonance
SEC-MALS size exclusion chromatography combined with multi-
angle light scattering
MCK multi-cycle kinetics
Fig. 1. Overview of the investigated
constructs of human peroxidasin-1.
PXDN-con2 comprises four immunoglobulin
(Ig) domains and the peroxidase domain
(POX) as well as the C-terminal von
Willebrand factor type C (VWC) domain and
forms trimers; PXDN-con3 is monomeric
and comprises the leucine rich repeat do-
main (LRR), the Ig domains and POX;
PXDN-con4 is monomeric and consists of
the four Ig domains and POX; PXDN-con5 is
monomeric and consists of the catalytic
peroxidase domain only.
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For recombinant expression, we chose the HEK 293F (Invitrogen)
suspension system. Cells were cultivated according to the Invitrogen
User Guideline. Cells were transfected as reported previously [21].
Hemin chloride was added to the culture medium to a final con-
centration of 5 μg mL−1 4 h after transfection to improve heme in-
corporation. Supernatants were harvested 5 days after transfection.
Purification of the different constructs (Fig. 1) followed a procedure
described previously [21,23]. In short, the harvested supernatant was
filtrated through a 0.45 μm PVDF membrane (Durapore) and con-
centrated to 100 mL using a Millipore Labscale TFF diafiltration system.
Subsequently, the sample was adjusted to 1 M NaCl and 20 mM imi-
dazole.
For purification of the His6-tagged proteins, 5 mL HisTrap FF col-
umns (GE Healthcare) loaded with nickel chloride were used. After
equilibration of the column with 100 mM sodium phosphate buffer (pH
7.4) containing 1 M NaCl and 20 mM imidazole, the sample was loaded
and washed with equilibration buffer. The protein was eluted using two
consecutive step gradients of 8% and 70% of 20 mM sodium phosphate
buffer, pH 7.4, 500 mM NaCl and 500 mM imidazole. Eluted fractions
were analysed by UV–vis spectroscopy and SDS-PAGE. Appropriate
fractions were pooled and washed 5 times with 100 mM sodium
phosphate buffer, pH 7.4, using Amicon Ultra-15 50 kDa cut-off cen-
trifugal filters (Merck Milipore).
2.3. Immunoprecipitation
Murine basement membrane extract (BME; 20 μg) was mixed with
10 μg of each construct and incubated at 21 °C for 1 h. Protein G
Dynabeads (Thermofisher) were coupled with an anti-His6 antibody
(Abcam mouse 1 × Anti-6 × His tag®) according to the manufacturer's
protocol and was washed once with 0.05% v/v Tween 20 in PBS
(PBST). The BME-construct mix was subsequently added to the coupled
Dynabeads and immunoprecipitated overnight with rotation at 4 °C. On
the next day, samples were washed 3 times with PBST, transferred into
clean tubes and eluted from the Protein G Dynabeads using the elution
buffer as per manufacturer's protocol to collect the immunoprecipitate.
2.4. Silver staining and immunoblotting
Immunoprecipitated samples were treated with NuPAGE reducing
buffer (1:10 dilution; Thermofisher) and heat denatured for 10 min at
70 °C in the presence of the NuPAGE sample buffer (1:4 dilution;
Thermofisher) and loaded onto NuPAGE 3–8% Tris-acetate gels run
under constant voltage (160 V) for 70 min. High molecular mass pro-
tein markers (HMW HiMark; 460-31 kDa; Thermofisher) were used as
calibration standards. Protein bands were detected by both silver
staining and immunoblotting using a rabbit polyclonal anti-laminin
antibody (Abcam ab11575, 1:2000 dilution) and an anti-rabbit-HRP
conjugated secondary antibody (1:5000 dilution), with the blots de-
veloped using a commercial chemiluminescence (ECL) reagent
(PerkinElmer, MA, USA), and imaged using a chemiluminescence im-
ager (Syngene, MD, USA).
2.5. Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed on a
Biacore T200 instrument (GE Healthcare). Laminin variants
(10 μg mL−1 in 10 mM sodium acetate buffer, pH 4.5) were covalently
immobilized on flow cells 2, 3 and 4 (immobilization levels: muLN111
~ 2650 RU; huLN111 ~ 2015 RU; huLN411 ~ 1615 RU), on a com-
mercially available CM5 chip (GE Healthcare) using the amine coupling
kit according to the manufacturer's protocol (GE Healthcare). In short,
the flow cells were activated with 1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide (EDC)/N-hydroxysulfosuccinimide (NHS) and excess re-
active carboxyl groups were blocked with ethanolamine. Flow cell 1
was activated and blocked in the same way and served as reference
surface (without ligand). Multi-cycle kinetics (MCK) experiments were
performed at 25 °C using increasing concentrations of PXDN-con3,
PXDN-con4, and PXDN-con5 respectively (0.14; 0.281; 0.5625; 1.125;
2.25; 4.5; 9 μM). 1 × PBS supplemented with 0.05% Tween 20 was
used as running buffer. Double referencing was accomplished by sub-
tracting the signal from injections of running buffer. The flow rate was
set to 30 μL min−1, association time was 7 min, dissociation was
monitored for 20 min. Complete regeneration of laminin variants was
achieved by one injection of glycine-HCl, pH 1.5 (30 s, 30 μL min−1)
followed by four injections of 10 mM NaOH (30 s each, 30 μL min−1)
Fig. 2. Immunoprecipitation of truncated
human peroxidasin-1 variants and basement
membrane extracts. (A) Silver-stained SDS-PAGE
under reducing conditions. Lanes 1–3 show im-
munoprecipitates containing monomeric PXDN-
con4, monomeric PXDN-con3 or trimeric PXDN-
con2. Lanes 4 and 5 represent negative controls.
BME, basement membrane extract; Ab, anti-His6
antibody. Lane 6: marker proteins. Lanes 7–9:
SDS-PAGE of recombinant glycosylated constructs
only (ctrl, control). (B) Immunoblot using anti-
laminin polyclonal antibody. Lanes 1–3 show im-
munoprecipitates containing monomeric PXDN-
con4, monomeric PXDN-con3 or trimeric PXDN-
con2. Lanes 4 and 5 represent negative controls
and lane 6 marker proteins. All gels and blots are
representatives of at least three independent ex-
periments.
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after every cycle. The integrity of the various ligands within one titra-
tion experiment was ensured by testing reproducibility of the 1.125 μM
analyte binding curve after application of the highest analyte con-
centration. Data were analysed with the Biacore Evaluation Software
version 3.1 (GE Healthcare). To determine the dissociation constant KD,
steady-state response units were plotted against analyte concentrations
and the data were fitted to a steady-state affinity model. All MCK ex-
periments were performed in triplicates.
3. Results
The truncated constructs PXDN-con2, PXDN-con3, PXDN-con4, and
PXDN-con5 (Fig. 1) with an N-terminal His6 tag were purified using
affinity chromatography and preparative size exclusion chromato-
graphy (SEC). PXDN-con2 forms trimers, whereas PXDN-con3, PXDN-
con4 and PXDN-con5 are monomeric proteins. Importantly, full length
homotrimeric PXDN is not included in this study because we (and also
other groups) have not been able to obtain sufficient amounts of cor-
rectly folded protein. The correct folding of the recombinant proteins
were probed routinely by SEC coupled to multi-angle light scattering
(MALS), circular dichroism and UV–vis spectroscopy as described re-
cently [21,23].
3.1. Laminin is a specific binding partner of human peroxidasin 1 (PXDN)
Purified distinct His6-tagged PXDN constructs were mixed with
murine extracellular basement membrane extract (which contains la-
minins, collagen IV, entactin and heparan sulphate proteoglcans) and
incubated with protein G coated with an anti-His6 antibody. The mix-
ture was immunoprecipitated, the attached proteins released, and these
then separated by electrophoresis under reducing conditions. Fig. 2A
compares the silver-stained IP mixtures with positive controls (ctrl) of
pure recombinant glycosylated constructs 2, 3 and 4 which have molar
masses of 130–170 kDa (right side of panel A). It has been demon-
strated that the full length PXDN has ten confirmed N-glycosylation
sites [seven on the peroxidase domain (POX), one on the Ig domains,
one in the C-terminal linker region between POX and the VWC module
and one on the VWC module] [18]. From the IP mixtures, only PXDN-
con3 (molar mass of glycosylated protein ~170 kDa) showed three
additional bands at molar masses ≫ 170 kDa suggesting co-
Fig. 3. Kinetics and affinity of binding of human
peroxidasin-1 construct, PXDN-con3, to murine
and human laminins. Determination of the dis-
sociation constants (KD) for the interaction of dif-
ferent laminin isoforms with PXDN-con3 via steady-
state analysis of double-referenced multi-cycle ki-
netics SPR experiments. Left: Titrations of (A) murine
laminin-111 (muLN111), (B) human laminin-111
(huLN111) and (C) human laminin-411 (huLN411)
with 7 different concentrations of PXDN-con3
(0.14–9.00 μM). Right: Corresponding plots of ana-
lyte concentrations versus steady-state responses and
the affinities (KD) determined thereof. All plots are
representatives of 3 independent measurements.
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precipitation of BME proteins. By contrast, trimeric construct 2 and
monomeric construct 4 (Fig. 2A) and monomeric construct 5 (not
shown) did not interact with BME under the applied conditions in-
dicating that the LRR domain plays an important role in binding of BME
proteins.
Next, we screened the IP mixtures with antibodies raised against
laminin resulting in the discovery of laminin as an interacting partner of
peroxidasin construct PXDN-con 3 (Fig. 2B). Typically, under reducing
conditions, the three glycosylated chains of laminin appear as two
bands on the gel, one at ~300 kDa corresponding to the β-chain and γ-
chain (theoretical protein molar masses of 230 kDa and 220 kDa, re-
spectively) and ~500 kDa indicative of the α-chain (theoretical protein
molar mass ~400 kDa) [24,25]. The band at around 200 kDa may re-
present a proteolytic fragment of laminin, which is still recognized by
the anti-laminin antibody. It should also be noted that the IP mixture
containing PXDN-con4 also showed a faint band at ~500 kDa upon
staining with the anti-laminin antibody, suggesting a weak interaction
of this construct with laminin.
3.2. The leucine-rich repeat domain of human peroxidasin 1 promotes
binding to laminin
The interaction of PXDN-con3 with murine and human laminin-111
was confirmed and characterised by SPR spectroscopy, with laminin-
111 serving as the ligand covalently coupled to the chip. Multi-cycle
kinetics (MCK) experiments were performed using increasing con-
centrations of PXDN-con3. Fig. 3A (left) shows the sensorgram of
PXDN-con3 associating with, and dissociating from, murine laminin-
111 (muLN111), the best characterised laminin isoform [24,25]. Both
the association and the dissociation occur in a multi-phasic manner,
most probably as a consequence of the heterogeneous orientation of the
amine coupled ligand on the chip surface, and the resulting variations
in accessibility of the binding site(s). The double-referenced MCK ex-
periments were analysed by plotting the response values 4 s before the
injection stop (i.e. under steady-state conditions) against the respective
PXDN-con3 concentration. The entire data set was then fitted to a
steady-state affinity model resulting in a dissociation constant (KD) of
1.5 μM, confirming that PXDN-con3 interacts specifically with laminin,
and quantifying this binding (Fig. 3A, right).
To probe whether laminin binding to PXDN-con3 is species or iso-
form-dependent, human laminin-111 (huLN111) and human laminin-
411 (huLN411) were covalently coupled to the chip surface and titrated
with PXDN-con3 as described above for muLN111. Similar binding
curves to those obtained for muLN111, were obtained for huLN111 and
huLN411 (Fig. 3B and C, left). Steady-state evaluation of the con-
centration dependent and saturable response curves (Fig. 3B and C,
right) resulted in very similar KD values, clearly indicating that the
modes of binding of PXDN-con3 to muLN111 and huLN111, as well as
isoform huLN411, are almost identical.
Since the immunoblots of the IP mixture containing PXDN-con4 also
indicated some weak interaction with laminin, SPR measurements were
also performed with PXDN-con4 and PXDN-con5 with muLN111.
Fig. 4A depicts the sensorgram of the interaction of PXDN-con4 with
muLN111. The shapes of the response curves are similar to PXDN-con3,
but the maximum experimental response (~61 RU) was only ~14% of
the maximum theoretical calculated response (~446 RU). Nevertheless,
steady-state analysis resulted in a similar dissociation constant (2.0 μM)
as for PXDN-con3 (Fig. 4B). The titration with PXDN-con5 (Fig. 4C and
D) gave 60% of the maximum theoretical response, but the KD value
was ~10 fold higher (i.e.: ~15 μM) compared to the PXDN-con3 and
PXDN-con4 constructs.
4. Discussion
Human peroxidasin 1 is an indispensable player in the basement
membrane synthesis [15,16,22]. Loss of integrity of the BM is asso-
ciated with severe developmental defects and pathologies [2,3]. As-
sembly of collagen IV generates one of the two major protein networks
of BMs. It assembles through oligomerization and non-covalent inter-
actions, and is subsequently stabilized by covalent cross-links including
the sulfilimine bonds synthesized by PXDN, and the allysine-derived
cross-links generated by lysyl oxidase and lysyl oxidase-like enzymes
[26]. However, it unknown how the highly reactive and potentially
damaging hypobromous acid [27] released by PXDN is able to generate
specific S]N bonds between adjacent collagen IV protomers, without
damaging neighbouring sites on collagen IV, or other BM molecules.
Together with thyroid peroxidase (TPO), PXDN catalyses an ana-
bolic reaction. In contrast to (diffusible) lactoperoxidase (LPO), eosi-
nophil peroxidase (EPO) and MPO, that each consist solely of a per-
oxidase domain, and are involved in non-specific immune defense
reactions, TPO is a membrane-anchored peroxidase, and PXDN contains
several non-enzymatic domains that might be expected to integrate and
regulate the peroxidase activity of peroxidasin 1. Although differing in
their structural composition, the main enzymatic reaction of all five
Fig. 4. Interaction between murine laminin-111
with human peroxidasin-1 constructs PXDN-con4
and PXDN-con5. Titration of murine laminin-111
(muLN111) with 0.14–9.00 μM PXDN-con4 and
0.78–20 μM PXDN-con5, respectively. Double-refer-
enced multi-cycle kinetics SPR experiments with
PXDN-con4 (A) and PXDN-con5 (C). Corresponding
plots of the equilibrium response units versus PXDN-
con4 (B) and PXDN-con5 (D) concentrations and the
determined KD values. The orange curves represent
duplicates of 0.5625 μM of PXDN-con4, and 3.15 μM
of PXDN-con5, respectively. (For interpretation of the
references to colour in this figure legend, the reader
is referred to the Web version of this article.)
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human heme peroxidases is two-electron oxidation of halide and
pseudohalide (thiocyanate) anions to the corresponding hypohalous
acids and hypothiocyanite, which are diffusible antimicrobial oxidants.
The capacity of those peroxidases to oxidize different anions depends
strongly on the post-translational modifications of the heme and con-
sequent alterations to the redox properties of the heme iron [21,28–32].
Human peroxidasin 1 is able to efficiently oxidize bromide to hypo-
bromous acid (HOBr), but not chloride to hypochlorous acid (HOCl)
[21]. To date it is unknown as whether, and how, the PXDN-typical
domains might restrict its mobility within the ECM, and foster the co-
localisation of the peroxidase domain with the NC1 domains of collagen
IV to avoid unspecific reactions of HOBr. So far, potential interaction
partners of the ECM networks and associated proteins could not be
identified.
In the present study, we have produced four different recombinant
constructs of PXDN with distinct domain compositions (Fig. 1). One of
the constructs, PXDN-con2 is trimeric, since it contains the alpha-he-
lical linker region and redox-sensitive cysteines close to the C-terminus
of the peroxidase domain, which are responsible for trimerization [23].
In contrast, PXDN-con3, PXDN-con4 and PXDN-con5 are monomeric
proteins [23]. Upon association of these four His-tagged proteins with
the anti-His6 antibody coupled Dynabeads and mixing with BME, only
laminin was immunopreciptated, as demonstrated by SDS-PAGE and
immunoblotting using polyclonal antibodies raised against laminin
(Fig. 2). This supports and confirms the conclusion that type IV collagen
does not form a stable complex with peroxidasin 1, as reported recently
[33]. These data suggest that interaction of PXDN with collagen IV and
its NC1 domains, may be transient in nature or mediated by another
ECM protein, such as the laminin isoforms described here.
The LRR domain in PXDN-con3 (Fig. 2B, lane 2) appears to be es-
sential for efficient immunoprecipitation of laminin. Neither trimeric
PXDN-con2, nor monomeric PXDN-con4 were able to promote pre-
cipitation of ECM proteins. The affinity of PXDN-con3 towards human
and mouse laminin-111 (i.e. α1β1γ1) was almost identical, suggesting
the presence of conserved binding motif(s). Moreover, laminin-411
(α4β1γ1), which contains a shorter α-chain due to an N-terminal
truncation, also bound to PXDN-con3 with a similar affinity. This sug-
gests that the N-terminal region of the α-chain of laminin is not es-
sential for binding of PXDN.
To date, there is an absence of high resolution structural data of full
length homotrimeric PXDN, or truncated variants. A potential reason
for this lack of structural data is the high flexibility of both the
monomeric and homotrimeric structures as demonstrated recently by
small-angle X-ray scattering (SAXS) [23]. This SAXS data indicates that
the POX domain (i.e. PXDN-con5) has an N-terminal flexible propeptide
region and a compact globular core catalytic structure, similar to that of
proMPO [34]. The monomeric construct PXDN-con4, which includes
the four Ig domains located N-terminally of the propeptide region of the
POX domain, is highly catalytically active [21,35]. The Ig domains have
been shown to support correct folding of the POX domain [18,21] and
thus to be essential for efficient sulfilimine bond formation in collagen
IV [33]. Both SAXS data and rotary shadowing images suggest sig-
nificant interaction of the Ig domains with the peroxidase domain and
with each other [34]. The homotrimeric construct PXDN-con2 differs
from PXDN-con4 at the C-terminus, with PXDN-con2 containing the
additional VWC domain. The latter is not involved in trimerization, and
is removed before secretion of peroxidasin 1 to the ECM [36]. It should
be noted that in the expression system used here, this processing step
does not, or only partially, occurs [34]. In any case, trimerization is
promoted by the amphipathic helix as well as by the conserved cy-
steines C736 and C1315. SAXS data as well as rotary shadowing, sug-
gest a triangular arrangement of the three compact core peroxidase
domains [34]. Moreover, modelling suggests free access for substrates
(hydrogen peroxide and bromide) to the respective heme cavities in this
trimeric construct [34]. A triangular arrangement of the POX domains
is also obvious by inspection of micrograph data of full length trimeric
peroxidasin from Drosophila [37]. The structures show a relatively
compact core similar to the triangular POX domains as seen in the SAXS
data [23,34]. The POX domains extend into three flexible arms, which
are most likely composed of the LRR and Ig domains [37].
Unfortunately, an in-solution structure of PXDN-con3 is not avail-
able so far, nor is anything known about the molecular basis of the
affinity of this construct to huLN111, muLN111 or huLN411. However,
our SPR data indicate that the POX domain must be involved in binding
to laminin. The measured SPR responses and calculated KD values of
PXDN-con4 and PXDN-con5 can be discussed on the basis of the
available structural data of peroxidasin variants outlined above. In
general, the binding capacity of the SPR chip surface depends on the
levels of immobilized laminin. The term maximum response (Rmax)
describes the binding capacity of the surface in terms of the response at
saturation. A theoretical Rmax value can be calculated assuming 1:1
binding and both the immobilized ligand and the analyte (i.e. PXDN
constructs) are active and fully accessible:
= ×Theoretical R analyte MW
ligand MW
RUmax immobilized ligand
The theoretical Rmax for binding of PXDN-con3 to muLN111 is ~532
RU, whereas the experimental value was measured as ~524 RU, which
is about 99% of the theoretical value. This is consistent with fully active
ligand and analyte. Compared to the theoretical Rmax of 446 RU of
PXDN-con4 binding to muLN111, the experimental Rmax is 61 RU,
which is only 14% of the theoretical Rmax. The POX domain in PXDN-
con4 is well folded but highly shielded by the very flexible Ig domains
as seen in the SAXS data [23]. As a consequence, there is a steric hin-
drance for the interaction between muLN111 and the POX domain in
PXDN-con4. Keeping in mind the high flexibility of the protein, it can
be assumed that at a distinct time point, only in a certain fraction of
PXDN-con4 molecules, the arrangement of Ig and POX domains allows
binding to laminin. In contrast, in the absence of the Ig domains (i.e.
PXDN-con5), the accessibility to the POX domain for laminin is higher
(reflected by 60% of the measured response), but the affinity is sig-
nificantly lower due to partial misfolding of the catalytic domain in the
absence of the stabilizing Ig domains. This might also apply to trimeric
PXDN-con2, which lacks both Ig and LRR domains and was not able to
immunoprecipitate laminin (Fig. 2). As mentioned above, we could not
study the interaction between laminin and full length homotrimeric
PXDN, which may alter the thermodynamics of binding. Based on the
available data, we hypothesize that the presence of the LRR domain in
PXDN-con3 impairs intimate interaction between the Ig domains,
thereby providing accessibility to the correctly folded catalytic domain,
which is supported by the micrograph of full length peroxidasin from
Drosophila described above and in Ref. [37]. Thus, the LRR domain
appears to promote high affinity binding of laminin-111 to the POX
domain of human peroxidasin 1.
Whilst these data provide compelling information on the binding of
human peroxidasin 1 to laminins, a number of critical questions remain.
These include the binding site(s) and chains from the laminin that are
involved, and the mode of interaction of the laminin-peroxidasin
complex with type IV collagen, and specifically the NC1 domains.
Furthermore, the source of hydrogen peroxide, which is essential for the
catalytic activity of PXDN and bromide oxidation is unclear, with recent
studies appearing to eliminate NADPH oxidases as a source [38,39].
Structural studies on potential complexes in-solution and/or by electron
microscopy would clearly be beneficial.
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